Vaccine Contract Manufacturing Market Size was valued at USD 3.3 Billion in 2023. The Vaccine Contract Manufacturing market industry is projected to grow from USD 3.7 Billion in 2024 to USD 7.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.50% during the forecast period (2024 - 2032). The increased prevalence of infectious diseases, outbreaks, and pandemics worldwide is one of the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for vaccine contract manufacturing is being driven by the rising vaccination rates worldwide. In the ever-evolving landscape of governmental and healthcare endeavors aimed at bolstering immunization coverage against the backdrop of infectious maladies, a pressing imperative emerges—a dire necessity for the expansion of vaccine production capacity. Within this exigent milieu, contract manufacturers emerge as veritable linchpins, wielding their prowess in the domain of vaccine production to furnish a panacea of flexible and scalable manufacturing solutions. Endowed with specialized facilities and unwavering fidelity to regulatory strictures, these entities furnish pharmaceutical behemoths with the instrumental means to orchestrate a seamless augmentation of vaccine production capabilities. The harrowing specter of the COVID-19 pandemic has served to magnify the imperative of fortifying vaccine manufacturing prowess, propelling a surge in investments geared towards the fecundation of vaccine development and production endeavors. As the apogee of vaccination rates is charted across the global expanse, the clamor for the services rendered by vaccine contract manufacturers is poised to ascend to vertiginous heights, heralding an epoch of unprecedented market growth. Enmeshed within the tapestry of the Vaccine Contract Manufacturing Market are the sinews of global health exigencies, wherein the specter of infectious disease outbreaks and the omnipresent shadow of pandemics serve as vanguards propelling the market's ascension. The burgeoning ubiquity of infectious pathogens, intertwined with the looming specter of bioterrorism, accentuates the exigency of vaccines as sentinels of public health. In this crucible of exigency, contract manufacturers emerge as valiant custodians, orchestrating a symphony of vaccine manufacturing prowess to assuage the tremors of global health crises.
The warp and weft of their operational ethos unfurl with alacrity in response to the tempestuous whims of outbreaks, such as the epoch-defining cataclysm of COVID-19. Their adeptness in marshaling resources to effectuate rapid escalations in production underpins the edifice of timely global vaccine accessibility. Moreover, the corridors of governmental and international coffers resound with the clarion call of investments channeled towards the augmentation of vaccine development and manufacturing, in a concerted bid to fortify the ramparts of pandemic preparedness and response. As the ebb and flow of global health vicissitudes persist in their inexorable dance, the echo of demand reverberates through the annals of vaccine contract manufacturing services, auguring a vista characterized by robust market growth in the epochs yet to unfurl.
Technology advancements in vaccine manufacturing are driving the growth of the Vaccine Contract Manufacturing Market. Innovations such as cell culture-based production, recombinant DNA technology, and mRNA vaccine platforms have revolutionized vaccine manufacturing processes, enabling faster and more efficient production. Contract manufacturers invest in these advanced technologies to enhance their manufacturing capabilities and meet the increasing demand for vaccines. Additionally, these technologies allow for the development of novel vaccine candidates targeting a wide range of infectious diseases, including emerging pathogens and bioterrorism threats. Furthermore, technological advancements enable contract manufacturers to improve vaccine quality, reduce production costs, and enhance scalability, making them attractive partners for pharmaceutical companies and governments seeking to expand vaccine production capacity. As technology continues to evolve, so does the vaccine contract manufacturing market revenue. For instance, Moderna signed a deal with the Canadian government to establish a messenger RNA vaccine manufacturing facility in an undisclosed location within Canada. This collaboration aims to provide Canadians with locally produced mRNA vaccines targeting respiratory viruses like SARS-CoV-2, influenza, and respiratory syncytial virus.
The Vaccine Contract Manufacturing Market segmentation, based on Vaccine Type, includes Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. In 2023, the Attenuated segment dominated the market, accounting for 35% of market revenue due to their effectiveness in generating robust and long-lasting immune responses against targeted pathogens. These vaccines are produced by weakening the disease-causing microorganism, allowing for safe administration while still eliciting a strong immune response. Additionally, attenuated vaccines often provide broader protection against various strains of pathogens, making them widely used in vaccination programs globally. Contract manufacturers specialize in producing attenuated vaccines, catering to the growing demand for effective and cost-efficient immunization solutions.
Inactivated vaccines are experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. These vaccines are produced by killing the disease-causing microorganism, making them safe for administration while still eliciting an immune response. Inactivated vaccines offer advantages such as improved stability and safety profiles, making them suitable for widespread use, especially in pediatric and elderly populations. Additionally, the increasing demand for influenza vaccines and other inactivated vaccines to prevent infectious diseases is driving growth in this segment of vaccine manufacturing.
Figure 1: Vaccine Contract Manufacturing Market, by Vaccine Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Vaccine Contract Manufacturing Market segmentation, based on Workflow, includes Downstream and Upstream. In 2023, the Downstream category generated the most income due to its critical role in vaccine production processes. This phase involves purification, concentration, and formulation of the vaccine candidate after upstream processing, ensuring the final product meets regulatory standards for safety, efficacy, and purity. Contract manufacturers specializing in downstream workflow offer expertise in purification techniques, such as chromatography and filtration, enabling the efficient production of high-quality vaccines. Additionally, downstream workflow optimization enhances manufacturing efficiency and reduces production costs, further driving its market dominance.
Upstream workflow is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. This phase involves cell culture, fermentation, and initial processing steps critical for vaccine production. With the increasing demand for novel vaccine candidates and the emergence of advanced bioprocessing technologies, there is a growing need for contract manufacturers specializing in upstream workflow. These manufacturers offer expertise in cell line development, bioreactor operation, and process optimization, enabling efficient and scalable production of vaccine candidates, thus driving growth in this segment.
The Vaccine Contract Manufacturing Market segmentation, based on Application, includes Human Use and Veterinary. In 2023, the Human Use category generated the most income due to the predominant focus on vaccines for preventing diseases in humans. Contract manufacturers specializing in human use applications are well-equipped to meet the stringent regulatory requirements and quality standards governing vaccine production for human use. Additionally, the high demand for vaccines to address public health concerns and prevent infectious diseases further drives the dominance of human use applications in vaccine contract manufacturing.
Veterinary application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. The growing awareness of animal health and welfare, coupled with increasing demand for livestock vaccines to prevent infectious diseases in animals, is driving growth in this segment. Additionally, advancements in biotechnology and genetic engineering are enabling the development of novel vaccines for veterinary use, further fueling the demand for contract manufacturing services in the veterinary vaccine market.
Vaccine Contract Manufacturing Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America has secured the largest market share in the Vaccine Contract Manufacturing Market due to several factors. These include a well-established pharmaceutical and biotechnology industry, advanced healthcare infrastructure, and strong regulatory frameworks supporting vaccine manufacturing. Additionally, the region is home to several leading vaccine manufacturers and contract manufacturing organizations, driving innovation and growth. Moreover, strategic partnerships between government agencies, academic institutions, and industry players further enhance North America's dominance in vaccine contract manufacturing.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: VACCINE CONTRACT MANUFACTURING MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Vaccine Contract Manufacturing market accounts for the second-largest market share due to investments in research and development. Europe has secured the second-largest market share in the Vaccine Contract Manufacturing Market due to several factors. These include a robust pharmaceutical and biotechnology sector, significant investments in research and development, and a skilled workforce. Additionally, Europe benefits from a strong regulatory environment and access to advanced manufacturing technologies, enabling contract manufacturers to meet stringent quality and safety standards. Moreover, the region's strategic location and extensive network of healthcare institutions contribute to its prominence in vaccine contract manufacturing. Further, the German Vaccine Contract Manufacturing market held the largest market share, and the UK Vaccine Contract Manufacturing market was the fastest growing market in the European region
The Asia-Pacific Vaccine Contract Manufacturing Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Vaccine Contract Manufacturing Market due to several factors. These include the increasing demand for vaccines in densely populated countries, rising investments in healthcare infrastructure, and the presence of a large skilled workforce. Additionally, favorable government initiatives, such as incentives for biopharmaceutical manufacturing and vaccine development, contribute to the region's growth. Moreover, the emergence of Asia Pacific as a manufacturing hub for pharmaceuticals and biotechnology further drives market expansion in the region. Moreover, China’s Vaccine Contract Manufacturing market held the largest market share, and the Indian Vaccine Contract Manufacturing market was the fastest growing market in the Asia-Pacific region.
Vaccine Contract Manufacturing Key Market Players & Competitive Insights
leading players in the Vaccine Contract Manufacturing Market, focusing on expanding their manufacturing capacities, enhancing technological capabilities, and forming strategic partnerships. These companies aim to meet the increasing demand for vaccines, especially in response to public health emergencies like the COVID-19 pandemic. Additionally, leading players are investing in research and market developments to develop innovative vaccine candidates and improve production efficiency. Furthermore, they are leveraging their expertise in regulatory compliance to ensure the quality and safety of vaccine manufacturing processes.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Vaccine Contract Manufacturing industry to benefit clients and increase the market sector. In recent years, the Vaccine Contract Manufacturing industry has offered some of the most significant advantages to Downstream. Major players in the Vaccine Contract Manufacturing market, including Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others, are attempting to increase market demand by investing in research and development operations.
Emergent BioSolutions Inc. is a global leader in vaccine contract manufacturing, offering end-to-end solutions for the development, manufacturing, and distribution of vaccines. With state-of-the-art facilities and advanced bioprocessing capabilities, Emergent specializes in producing vaccines for infectious diseases, biodefense, and public health emergencies. The company's comprehensive services include process development, technology transfer, cGMP manufacturing, fill-finish operations, and regulatory support. Emergent collaborates closely with government agencies, pharmaceutical companies, and nonprofit organizations to address global health challenges and advance vaccine development initiatives. Leveraging its expertise and commitment to quality, Emergent plays a critical role in enhancing global vaccine preparedness and response efforts, ensuring timely access to safe and effective vaccines for populations worldwide.
Wuxi Biologics is a leading global contract development and manufacturing organization (CDMO) specializing in biologics, including vaccine contract manufacturing. With state-of-the-art facilities and extensive expertise in bioprocessing, Wuxi Biologics offers end-to-end solutions for the development, manufacturing, and commercialization of vaccines. The company's services include cell line development, process optimization, cGMP manufacturing, and fill-finish operations tailored to meet the specific needs of vaccine developers. Wuxi Biologics collaborates with pharmaceutical companies, academic institutions, and government agencies to accelerate vaccine development timelines and ensure regulatory compliance. Through its commitment to innovation, quality, and customer satisfaction, Wuxi Biologics contributes to advancing global vaccine manufacturing capabilities and addressing public health challenges worldwide.
Key Companies in the Vaccine Contract Manufacturing market include
Vaccine Contract Manufacturing Industry Developments
June 2022: Merck and Agilent Technologies partnered to enhance process analytical technologies for downstream processing and address gaps in this area.
January 2022: INCOG Biopharma Services, an Indiana-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, declared that the construction of its manufacturing facility and global headquarters in Fishers is close to finishing.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 3.3 Billion |
| Market Size 2024 | USD 3.7 Billion |
| Market Size 2032 | USD 7.9 Billion |
| Compound Annual Growth Rate (CAGR) | 11.50% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Vaccine Type, Workflow, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others |
| Key Market Opportunities | ·      Digitalization and Data Analytics and Capacity Expansion and Flexibility |
| Key Market Dynamics | ·      Rising Vaccination Rates and Global Health Concerns |
Frequently Asked Questions (FAQ) :
The Vaccine Contract Manufacturing Market size was valued at USD 3.3 Billion in 2023.
The global market is projected to grow at a CAGR of 11.50% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Emergent BioSolutions Inc., Catalent, Inc., Lonza Group AG, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Samsung Biologics, Boehringer Ingelheim, Novavax, Inc., BioNTech SE, CSL Limited and Others Company.
The Attenuated category dominated the market in 2023.
The Human Use category had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
